JPRN-jRCT2031200041进行中（未招募）2 期
A phase II trial of Atezolizumab for patients with unresectable alveolar soft tissue sarcoma - ALBERT trial
Yonemori Kan0 个研究点目标入组 20 人开始时间: 2020年6月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients must have histologically confirmed alveolar soft part sarcoma
- •2) Not curable by surgery
- •3) No symptomatic brain metastases, cancerous meningitis, spinal metastases requiring surgical intervention at the time of registration
- •4) No pericardial effusion, pleural effusion, or ascites with requiring treatment
- •5) Age at the time of registration is 16 years or older
- •6) ECOG performance status is 0 or 1
- •7) Having one or more measurable lesions confirmed by CT within 28 days before registration (Brain tumor must be confirmed by brain-enhanced MRI)
- •8) No prior treatment with anti-PD-1 or anti-PD-L1 therapeutic antibody
- •9) Not received systemic administration of corticosteroids(Equivalent to prednisolone> 10 mg / day) or immunosuppressant within 14 days before registration
- •10) Not received anti-cancer drug or other study drug within 28 days before registration
- •11) Not received operation under general anesthesia within 28 days before registration
- •12) Not received radiation therapy within 28 days before registration
- •13) Not received radiopharmaceutical within 56 days before registration
- •14) Having all laboratory tests performed within 14 days before registration are the values are within the following range.Patients should not receive administration of G-CSF and/or blood transfusion within 14 days before the blood collection
- •(1) Neutrophil count => 1,000/mm3
- •(2) Platelet count => 10.0 x 104/mm3
- •(3) Hemoglobin => 8.0 g/dL
- •(4) AST <= 100 U/L (allow AST <= 150 U/L with liver metastasis)
- •(5) ALT <= 100 U/L (allow ALT <= 150 U/L with liver metastasis)
- •(6) Total bilirubin <= 1.5 mg/dL
- •(7) Creatinine <= 1.5 mg/dL
- •15) => 92% of SpO2 under room air conditions within 14 days before registration
- •16) Consent to contraception and limited breast-feeding
- •17) Written informed consent.
排除标准
- •1)Active double cancer (except for completely resected basal cell carcinoma, squamous cell carcinoma, carcinoma in situ, intramucosal cancer, superficial bladder cancer, gastrointestinal cancer resected by ESD or EMR, and other cancer free of relapse for more than 5 years).
- •2)Infection requiring systemic therapy.
- •3)Active gastrointestinal ulceration.
- •4)Current or previous interstitial lung disease or pulmonary fibrosis diagnosed based on imaging or clinical findings
- •5)Active radiation pneumonitis pneumonitis or Infectious pneumonia diagnosed based on imaging
- •6)Current or previous severe hypersensitive reaction to antibody drugs.
- •7)Active autoimmune disease or previous Chronic / recurrent autoimmune disease
- •8)HIV antibody-positive, or HTLV-1 antibody-positive, or HBs antigen-positive, or HCV antibody-positive (those who are HCV-RNA-negative are not excluded even if HCV antibody-positive)
- •9)Though HBs antigen-negative, HBs antibody-positive and/or HBc antibody-positive, and HBV-DNA quantitative test positive HBs
- •10)Pregnant or breast-feeding women, or women suspected of being pregnant.
- •11)Psychiatric diseases or psychological symptoms interfering with participation in the trial.
研究者
相似试验
招募中
2 期
OGIK2301(RELIANCE)on-small cell lung cancerNon-small cell lung cancerJPRN-jRCTs071230065Yamaguchi Masafumi33
尚未招募
Unknown
A single-arm phase II trial of Atezolizumab and Bevacizumab with combined radiotherapy in advanced hepatocellular carcinoma with portal vein invasioKCT0008733Yonsei University Health System, Severance Hospital51
招募中
2 期
PhaseII study of Atezolizumab plus Chemotherapy in PS 2 Patients With Non-Sq NSCLCJPRN-jRCTs041210030Murakami Haruyasu20
进行中（未招募）
1 期
Study to assess efficacy of Atezolizumab in combination with Carboplatin Plus Pemetrexed in patients who are chemotherapy-naïve and have stage IV non-squamous non-small cell lung cancer with asymptomatic brain metastases (ATEZO-BRAIN)Atezolizumab combined with carboplatin and pemetrexedMedDRA version: 20.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2017-005154-11-ESSpanish Lung Cancer Group (SLCG/GECP)40
进行中（未招募）
1 期
Atezolizumab and bevacizumab study for non small cell lung cancer patients with high-intermediate tumour mutation burdeon small cell lung cancerMedDRA version: 20.0 Level: PT Classification code 10061873 Term: Non-small cell lung cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004654-17-ESFundación GECP102